Vectura Group plc, (Vectura) along with its subsidiaries, is principally engaged in the research and development of therapeutic products and drug delivery systems for human use. The Company is focused on the development of inhaled pharmaceuticals. It has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to pharmaceutical companies. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis. It has development collaborations with a range of pharmaceutical companies, including Boehringer Ingelheim, Novartis and Chiesi. On January 18, 2007, Vectura acquired Innovata plc and its subsidiaries.